Based on these findings, we suggest therapeutic targeting of CIP2A, an established endogenous inhibitor of PP2A [10, 11, 14] as a novel approach to simultaneous target both the luminal type mass of prostate cancer, as well as the tumor initiating capacity of the SC populations (Figure 4D). This evidence concerns the gene CIP2A and Familial prostate cancer.